Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05284019 · ClinicalTrials.gov registry record · Phase 4
Real World Effectiveness of Eptinezumab in Participants With Migraine
A Phase 4 study, sponsored by H. Lundbeck A/S.
- Terminated
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT05284019 is a Phase 4 study that was terminated before completion, run by H. Lundbeck A/S. The registered enrollment target is 32 participants.
The verdict
NCT05284019, a Phase 4 study, was terminated before completion, sponsored by H. Lundbeck A/S.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported outcomes.
Interventions
- DRUG Eptinezumab
- DRUG Galcanezumab
- DRUG Fremanezumab
- DRUG Erenumab
- DRUG Onabotulinumtoxin-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-03-04 |
| Est. Completion | 2023-04-14 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05284019
The ClinicalTrials.gov registry entry for NCT05284019 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Eptinezumab is the first listed.
NCT05284019 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05284019 about?
NCT05284019 is a clinical study titled "Real World Effectiveness of Eptinezumab in Participants With Migraine". The purpose of this study is to examine how eptinezumab compares to other advanced preventive medications in a real-world community setting in adult participants with episodic migraine (EM) or chronic migraine (CM). These objectives include exploring the comparative effectiveness on patient reported...
What is the current status of trial NCT05284019?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2022-03-04. Estimated completion is 2023-04-14.
What interventions are being tested in trial NCT05284019?
The interventions under investigation include: Eptinezumab (DRUG), Galcanezumab (DRUG), Fremanezumab (DRUG), Erenumab (DRUG), Onabotulinumtoxin-A (DRUG).
Who is sponsoring clinical trial NCT05284019?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.